Vacuna AIDSVAX B/B para la prevención de la infección por VIH-1 en adultos
Este estudio tiene como objetivo evaluar la efectividad de la vacuna AIDSVAX B/B en la prevención de la infección por VIH-1 en adultos.
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Infecciones Transmitidas por la Sangre+14
+ Enfermedades Urogenitales
+ Enfermedades Genitales
Estudio de Prevención
Resumen
Volunteers receive 7 blinded, intramuscular vaccinations (at Months 0, 1, 6, 12, 18, 24, 30) containing either the AIDSVAX B/B vaccine or a placebo (aluminum adjuvant only). Volunteers are randomized in a 2 to 1 vaccine-to-placebo ratio. HIV-uninfected persons are followed for a total of 16 visits beginning at screening and continuing until Month 36. Patients who become HIV infected during study are followed every 4 months for at least 24 months.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 5000 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Prevención
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.De 18 a 60 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Exclusion Criteria You will not be eligible for this study if you: Use injection drugs. Have a history of any serious diseases or conditions, including lymphoma. Have ever received an HIV vaccine. Have taken post-exposure treatment to prevent HIV infection within 4 weeks prior to study entry. Are planning to take other HIV vaccines during this study. Are pregnant. Have taken certain medications or received certain therapies, including chemotherapy and radiation. Have received certain vaccines within 2-4 weeks prior to study entry. You may be eligible for this study if you: Are HIV-negative. Are between 18 and 60 years old. Are available for 3 years of follow-up. Agree to use effective methods of birth control during the study and for 90 days after. Are one of the following: A woman who is currently in a sexual relationship with an HIV-positive man. A woman who has had more than one male partner and at least one sexually transmitted disease (STD) within the past 12 months. A man who has sex with men and has had anal intercourse within the past 12 months. (You will not be eligible if you have been in the same relationship with only one HIV-negative man for at least 12 months.)
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene 67 ubicaciones
Univ of Alabama at Birmingham
Birmingham, United StatesAbrir Univ of Alabama at Birmingham en Google MapsPhoenix Body Positive
Phoenix, United StatesArizona Clinical Research Ctr Inc
Tucson, United StatesUniv of California / UCI Med Ctr
Orange, United States